Eclizumab in the treatment of myasthenia gravis crisis complicating invasive thymoma: A case study of efficacy

2Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.

Abstract

A 40-year-old male patient was diagnosed with invasive thymoma and myasthenia gravis in 2015. In 2016 and 2017, he experienced myasthenic crises, with an increase in size of invasive thymoma. In 2018, he received chemotherapy for the invasive thymoma. After 2 months, his symptoms rapidly progressed to myasthenic crisis with severe bulbar and respiratory symptoms, despite the significant effect of chemotherapy for the thymoma. High-dose corticosteroid, multiple plasma exchanges, and intravenous immunoglobulin did not improve the symptoms. Thus, eculizumab was administered, resulting in an improvement in his conditions. To our knowledge, this is the first report showing that eculizumab may improve myasthenic crisis with invasive thymoma.

Cite

CITATION STYLE

APA

Yoshizumi, K., Kimura, T., Ukon, S., Watanabe, S., Kasama, S., & Takeda, M. (2020). Eclizumab in the treatment of myasthenia gravis crisis complicating invasive thymoma: A case study of efficacy. Clinical Neurology, 60(12), 865–868. https://doi.org/10.5692/CLINICALNEUROL.CN-001483

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free